MGI Pharma MOGN New patents, anti cancer Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (1790)	10/22/2007 6:34:54 AM
From: Icebrg	Read Replies (1) of 1826

MGI Pharma "neutral," target price reduced Thursday, October 18, 2007 8:48:07 AM ET Robert W. Baird NEW YORK, October 18 (newratings.com) - Analysts at Robert W Baird reiterate their "neutral" rating on MGI Pharma Inc (MOGN.NAS), while raising their estimates for the company. The target price has been reduced from $30 to $27. In a research note published this morning, the analysts mention that the company has posted robust 3Q07 nom-GAAP EPS for the current quarter ahead of estimates and consensus. The management has guided 4Q07 sequential growth at 10% viewing revenue recovery of $72 million ahead of expectations from the 1H07 generic Sofran challenge. The EPS estimates for 2007 and 2008 have been raised from $0.61 to $0.74 and from $0.81 to $1.17 respectively reflecting nice revenue benefit changes.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next